Aspen Pharmacare, a leading global pharmaceutical company headquartered in South Africa (ZA), has established itself as a key player in the healthcare industry since its founding in 1850. With a strong presence in over 50 countries, Aspen operates primarily in the areas of generic and branded pharmaceuticals, as well as consumer healthcare products. The company is renowned for its diverse portfolio, which includes anaesthetics, thrombosis, and oncology medications, setting it apart through a commitment to quality and innovation. Aspen's strategic acquisitions and partnerships have bolstered its market position, making it one of the largest pharmaceutical manufacturers in Africa. Notable achievements include its rapid expansion into international markets and a focus on sustainable healthcare solutions, reinforcing its reputation as a trusted provider in the global pharmaceutical landscape.
How does Aspen Pharmacare's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Aspen Pharmacare's score of 59 is higher than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Aspen Pharmacare reported total carbon emissions of approximately 32468000 kg CO2e for Scope 1, 108515000 kg CO2e for Scope 2, and 200000000 kg CO2e for Scope 3 emissions, which includes about 150000000 kg CO2e from purchased goods and services. This represents a significant increase in emissions compared to 2023, where Scope 1 emissions were 37000000 kg CO2e and Scope 2 emissions were 112000000 kg CO2e, with no Scope 3 data disclosed. Aspen Pharmacare has set ambitious climate commitments, aiming to reduce global carbon dioxide emissions by 45% by 2030 relative to 2010 levels, with a long-term goal of achieving net zero emissions around mid-century. Specific targets include a 30% reduction in Scope 1 and Scope 2 emissions from a 2020 baseline by 2030. Notably, the company has previously achieved a 64% reduction in Scope 1 emissions from 18896000 kg CO2e to 6774000 kg CO2e between 2012 and 2013, and a 44% reduction in Scope 2 emissions from 158035 kg CO2e to 88008 kg CO2e in the same timeframe. Aspen Pharmacare's emissions data and climate commitments are sourced directly from the organisation itself, with no data cascaded from a parent company. The company continues to focus on enhancing its sustainability practices and reducing its carbon footprint across all scopes.
Access structured emissions data, company-specific emission factors, and source documents
2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 16,609,000 | - | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 37,278,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | - | 00,000,000 | - | - | - | - | - | - | - | - | 00,000,000 | 00,000,000 | - | - | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aspen Pharmacare is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.